STAT1 and STAT3 gain of function: clinically heterogenous immune regulatory disorders
The identification of STAT1 gain-of-function (GOF) in 2011 and STAT3 GOF in 2014 has advanced our understanding of the host immunity along the JAK/STAT pathway and allowed targeted treatment approaches. We review the clinical features and pathogenesis of STAT1 and STAT3 GOF and how this has shaped n...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/386370 |
| Acceso en línea: | http://hdl.handle.net/10261/386370 https://api.elsevier.com/content/abstract/scopus_id/85208160872 |
| Access Level: | acceso abierto |
| Palabra clave: | Immune regulatory disorders Jak inhibitors sTAT1 gain of function sTAT3 gain of function |
| Sumario: | The identification of STAT1 gain-of-function (GOF) in 2011 and STAT3 GOF in 2014 has advanced our understanding of the host immunity along the JAK/STAT pathway and allowed targeted treatment approaches. We review the clinical features and pathogenesis of STAT1 and STAT3 GOF and how this has shaped new approaches to therapy. |
|---|